**Abstract**

**Background:** Second-generation antipsychotics (SGAs), such as olanzapine, are used to treat schizophrenia; however, they have minimal benefits for cognitive deficits and cause metabolic side-effects such as obesity \[1, 2\]. Obesity has been linked to increased cognitive impairment \[3\], complicating the health issues of people with schizophrenia. Liraglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist with anti-obesity and neuroprotective properties \[4, 5\]; however, whether liraglutide can improve cognition during olanzapine treatment is unclear. The aim of this study was to examine the effects of liraglutide co-treatment on cognition and metabolic parameters during olanzapine treatment.

**Methods:** Sprague-Dawley rats were administered olanzapine (2mg/kg), liraglutide (0.4mg/kg), olanzapine+liraglutide co-treatment or vehicle (control) (n=12/group) for six weeks. Body weight, food intake and locomotor activity were recorded. Novel object recognition (NOR) and T-maze tests were conducted to examine recognition and working memory. Post-mortem white adipose tissue weight was recorded.

**Results:** Olanzapine caused significant body weight gain and increased white adipose tissue mass (p\<0.05 vs control), whereas liraglutide co-treatment significantly reduced body weight and adiposity (p\<0.001 vs olanzapine). Olanzapine induced hypolocomotion (p\<0.001 vs control), whereas liraglutide co-treatment significantly increased locomotor activity (p\<0.05 vs olanzapine). In the NOR test, olanzapine-treated rats spent significantly less time exploring the novel object, and this was significantly improved in the liraglutide co-treatment group (p\<0.01 vs olanzapine). There was no effect of treatment on correct entries in the T-maze test (p\>0.05 vs control).

**Conclusion:** This study demonstrates that liraglutide co-treatment can improve locomotor activity, decrease adiposity and prevent weight gain side-effects associated with olanzapine administration. Liraglutide co-treatment was able to improve recognition memory impairment caused by olanzapine treatment; however, it had no effect on working memory. Further studies are required to understand the mechanisms underlying these changes, and to elucidate whether a link exists between olanzapine-induced obesity and liraglutide's effect on cognition.
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